 | Up a level |
Poliaková Turan, Michaela; Riedo, Rahel; Medo, Matúš; Pozzato, Chiara; Friese-Hamim, Manja; Koch, Jonas Paul; Coggins, Si'Ana A; Li, Qun; Kim, Baek; Albers, Joachim; Aebersold, Daniel M; Zamboni, Nicola; Zimmer, Yitzhak; Medová, Michaela (2024). E2F1-associated purine synthesis pathway is a major component of the MET-DNA damage response network. Cancer research communications, 4(7), pp. 1863-1880. American Association for Cancer Research 10.1158/2767-9764.CRC-23-0370
Nisa, Lluís; Francica, Paola; Giger, Roland; Medo, Matúš; Eliçin, Olgun; Friese-Hamim, Manja; Wilm, Claudia; Stroh, Christopher; Bojaxhiu, Beat; Quintin, Aurélie; Caversaccio, Marco D.; Dettmer, Matthias S.; Buchwalder, Mélanie; Brodie, Tess M.; Aebersold, Daniel M.; Zimmer, Yitzhak; Carey, Thomas E.; Medova, Michaela (2020). Targeting the MET receptor tyrosine kinase as a strategy for radiosensitization in loco-regionally advanced head and neck squamous cell carcinoma. Molecular cancer therapeutics, 19(2), pp. 614-626. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-18-1274
Friese-Hamim, Manja; Bladt, Friedhelm; Locatelli, Giuseppe; Stammberger, Uz; Blaukat, Andree (2017). The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. American journal of cancer research, 7(4), pp. 962-972. e-Century Publishing Corporation
